Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 2, 2026, 6:41 PM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 985–1008 of 6,848 matching trials from the live ClinicalTrials.gov search.
Filters: Orlando, Florida Clear all
Completed Phase 3 Interventional Results available

Study Utilizing Rilonacept in Gout Exacerbations

NCT00855920
View directory record Official record
Conditions
Acute Gout Flare
Interventions
Rilonacept, Indomethacin, Placebo (for Indomethacin), Placebo (for Rilonacept)
Drug · Other
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years to 70 Years
Enrollment
225 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
44
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mesa, Arizona + 40 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2017 · Synced Nov 2, 2026, 6:41 PM EST
Completed Phase 3 Interventional Results available

VEC-162 Study in Adult Patients With Primary Insomnia

NCT00548340
View directory record Official record
Conditions
Primary Insomnia
Interventions
VEC-162 20 mg, Placebo, VEC-162 50 mg
Drug
Lead sponsor
Vanda Pharmaceuticals
Industry
Eligibility
18 Years to 64 Years
Enrollment
322 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
35
States / cities
Birmingham, Alabama • Hot Springs, Arkansas • Little Rock, Arkansas + 32 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2014 · Synced Nov 2, 2026, 6:41 PM EST
Recruiting Phase 4 Interventional

A Study to Evaluate the Efficacy of AXS-05 Compared to Bupropion in Preventing the Relapse of Depressive Symptoms

NCT06223880
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
AXS-05, Bupropion
Drug
Lead sponsor
Axsome Therapeutics, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
40
States / cities
Bellflower, California • Lafayette, California • Oceanside, California + 34 more
Source: ClinicalTrials.gov public record
Updated Jan 23, 2025 · Synced Nov 2, 2026, 6:41 PM EST
Completed Phase 3 Interventional Accepts healthy volunteers Results available

COVID-19 Study Assessing the Efficacy and Safety of Anti-Spike SARS CoV-2 Monoclonal Antibodies for Prevention of SARS CoV-2 Infection Asymptomatic in Healthy Adults and Adolescents Who Are Household Contacts to an Individual With a Positive SARS-CoV-2 RT-PCR Assay

NCT04452318
View directory record Official record
Conditions
Healthy Participants
Interventions
REGN10933 + REGN10987, Placebo
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
1 Day and older
Enrollment
3,303 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
132
States / cities
Mesa, Arizona • Tucson, Arizona • La Mesa, California + 94 more
Source: ClinicalTrials.gov public record
Updated May 15, 2023 · Synced Nov 2, 2026, 6:41 PM EST
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Study to Evaluate the Pharmacokinetics of Lemborexant (E2006) and Its Metabolites in Subjects With Mild and Moderate Hepatic Impairment Compared to Healthy Subjects

NCT03440424
View directory record Official record
Conditions
Hepatic Impairment
Interventions
Lemborexant
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years to 79 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
2
States / cities
Miami, Florida • Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Mar 20, 2020 · Synced Nov 2, 2026, 6:41 PM EST
Completed Phase 2 Interventional Results available

Phase II Trial of Pimasertib Versus Dacarbazine in N-Ras Mutated Cutaneous Melanoma

NCT01693068
View directory record Official record
Conditions
N-Ras Mutated Locally Advanced or Metastasis Malignant Cutaneous Melanoma
Interventions
Pimasertib, Dacarbazine
Drug
Lead sponsor
EMD Serono
Industry
Eligibility
18 Years and older
Enrollment
194 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
15
States / cities
Birmingham, Alabama • Tucson, Arizona • San Francisco, California + 12 more
Source: ClinicalTrials.gov public record
Updated Jan 5, 2018 · Synced Nov 2, 2026, 6:41 PM EST
Terminated Phase 3 Interventional Results available

Reduced Intensity Regimen vs Myeloablative Regimen for Myeloid Leukemia or Myelodysplastic Syndrome (BMT CTN 0901)

NCT01339910
View directory record Official record
Conditions
Leukemia, Myelocytic, Acute
Interventions
Fludarabine and Busulfan, Fludarabine and Melphalan, Busulfan and Fludarabine, Busulfan and Cyclophosphamide, Cyclophosphamide and Total Body Irradiation
Drug
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years to 65 Years
Enrollment
272 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
32
States / cities
Phoenix, Arizona • La Jolla, California • Gainesville, Florida + 27 more
Source: ClinicalTrials.gov public record
Updated Jan 4, 2023 · Synced Nov 2, 2026, 6:41 PM EST
Terminated Not applicable Interventional Results available

Intrathecal Morphine Compared to Conventional Medical Management for Pain Control and Opioid-related Side Effects

NCT01924182
View directory record Official record
Conditions
Chronic Pain
Interventions
SynchroMed Infusion System and Intrathecal Morphine Sulfate, Conventional Medicine
Device · Other
Lead sponsor
MedtronicNeuro
Industry
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
6
States / cities
Homewood, Alabama • Napa, California • Walnut Creek, California + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 29, 2018 · Synced Nov 2, 2026, 6:41 PM EST
Not listed Not applicable Interventional

Gamified Rehab vs Take-home Packet Rehab for Non-specific Low Back Pain

NCT05573932
View directory record Official record
Conditions
Non-specific Low Back Pain
Interventions
Leaderboard, Take-home packet
Other
Lead sponsor
University of Central Florida
Other
Eligibility
18 Years to 45 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Nov 28, 2023 · Synced Nov 2, 2026, 6:41 PM EST
Completed Phase 3 Interventional

COX-2 Inhibitor Study In Patients With Rheumatoid Arthritis

NCT00113308
View directory record Official record
Conditions
Arthritis, Rheumatoid
Interventions
GW406381
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
2,208 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
105
States / cities
Anniston, Alabama • Birmingham, Alabama • Huntsville, Alabama + 85 more
Source: ClinicalTrials.gov public record
Updated Mar 14, 2017 · Synced Nov 2, 2026, 6:41 PM EST
Completed Not applicable Interventional

Low-Load Blood Flow Restriction on Patients With Multiple Sclerosis

NCT05177952
View directory record Official record
Conditions
Training Study, Multiple Sclerosis, Blood Flow Restriction
Interventions
Blood Flow Restriction, Standard of Care
Other
Lead sponsor
University of Central Florida
Other
Eligibility
18 Years to 55 Years · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Jun 11, 2024 · Synced Nov 2, 2026, 6:41 PM EST
Completed Phase 3 Interventional

Efficacy Study of MPC-7869 to Treat Patients With Alzheimer's

NCT00105547
View directory record Official record
Conditions
Alzheimer Disease, Dementia
Interventions
MPC-7869
Drug
Lead sponsor
Myrexis Inc.
Industry
Eligibility
55 Years and older
Enrollment
1,600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
132
States / cities
Alabaster, Alabama • Huntsville, Alabama • Mesa, Arizona + 111 more
Source: ClinicalTrials.gov public record
Updated May 5, 2009 · Synced Nov 2, 2026, 6:41 PM EST
Completed Phase 3 Interventional Results available

Efficacy and Safety Study of Benralizumab to Reduce OCS Use in Patients With Uncontrolled Asthma on High Dose Inhaled Corticosteroid Plus LABA and Chronic OCS Therapy

NCT02075255
View directory record Official record
Conditions
Asthma
Interventions
Benralizumab, Placebo
Biological
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 75 Years
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
20
States / cities
Los Angeles, California • Centennial, Colorado • Denver, Colorado + 16 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2018 · Synced Nov 2, 2026, 6:41 PM EST
Completed Phase 3 Interventional Results available

A Phase 3 Efficacy and Safety Study of Intra-articular CNTX-4975-05 (Capsaicin) vs Placebo in Subjects With OA Knee Pain

NCT03429049
View directory record Official record
Conditions
Osteoarthritis, Knee
Interventions
CNTX-4975-05, Placebo
Drug
Lead sponsor
Centrexion Therapeutics
Industry
Eligibility
40 Years to 95 Years
Enrollment
332 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
33
States / cities
Birmingham, Alabama • Mobile, Alabama • Tucson, Arizona + 28 more
Source: ClinicalTrials.gov public record
Updated Jul 26, 2022 · Synced Nov 2, 2026, 6:41 PM EST
Completed Phase 2 Interventional Results available

Phase II Study for Previously Untreated Subjects With Non Small Cell Lung Cancer (NSCLC) or Small Cell Lung Cancer (SCLC)

NCT00527735
View directory record Official record
Conditions
Lung Cancer, Small Cell Lung Cancer, Carcinoma, Non-Small-Cell Lung
Interventions
Ipilimumab, Placebo, Paclitaxel, Carboplatin
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
334 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
27
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Tucson, Arizona + 24 more
Source: ClinicalTrials.gov public record
Updated Jul 18, 2018 · Synced Nov 2, 2026, 6:41 PM EST
Active, not recruiting Not applicable Interventional

Amplatzer Amulet LAAO vs. NOAC

NCT04226547
View directory record Official record
Conditions
Atrial Fibrillation, Stroke, Bleeding
Interventions
Left Atrial Appendage Occlusion (Amplatzer Amulet LAA Occluder), Non-Vitamin K Oral Antagonists
Device · Drug
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
18 Years and older
Enrollment
2,650 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2031
U.S. locations
79
States / cities
Birmingham, Alabama • Huntsville, Alabama • Phoenix, Arizona + 65 more
Source: ClinicalTrials.gov public record
Updated Feb 10, 2026 · Synced Nov 2, 2026, 6:41 PM EST
Completed Phase 3 Interventional Results available

A Study of Semagacestat for Alzheimer's Patients

NCT01035138
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
semagacestat
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
55 Years and older
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
41
States / cities
Phoenix, Arizona • Sun City, Arizona • Tucson, Arizona + 38 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2014 · Synced Nov 2, 2026, 6:41 PM EST
Completed Phase 2 Interventional

4-Week, Multi-center Dose-Ranging Study for the IBS-C in Pts. 6 to <12 Yrs

NCT06553547
View directory record Official record
Conditions
Irritable Bowel Syndrome With Constipation (IBS-C)
Interventions
Tenapanor, Placebo
Drug
Lead sponsor
Ardelyx
Industry
Eligibility
6 Years to 11 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
20
States / cities
Little Rock, Arkansas • Hartford, Connecticut • Miami, Florida + 15 more
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Nov 2, 2026, 6:41 PM EST
Recruiting Phase 4 Interventional

Secukinumab Open Label Roll-over Extension Protocol

NCT04638647
View directory record Official record
Conditions
Autoimmunity, Inflammation
Interventions
Secukinumab s.c. injection
Biological
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
6 Years to 100 Years
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2030
U.S. locations
28
States / cities
Fullerton, California • La Mesa, California • San Leandro, California + 25 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Nov 2, 2026, 6:41 PM EST
Recruiting Phase 2 Interventional

A Study to Evaluate the Effectiveness of Two Doses of AP-472 as Adjunctive Therapy to Levodopa in Parkinson's Disease (PD) Participants With Motor Fluctuations

NCT07432958
View directory record Official record
Conditions
Parkinson Disease
Interventions
AP-472, Placebo
Drug · Other
Lead sponsor
Appello Pharmaceuticals, Inc.
Industry
Eligibility
30 Years to 80 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
30
States / cities
Little Rock, Arkansas • Carlsbad, California • Los Alamitos, California + 25 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2026 · Synced Nov 2, 2026, 6:41 PM EST
Completed Phase 3 Interventional Results available

A Study to Assess the Efficacy and Safety of TC-5214 as an Adjunct Therapy in Patients With Major Depressive Disorder (MDD)

NCT01157078
View directory record Official record
Conditions
Major Depressive Disorder, Depression
Interventions
TC-5214, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 65 Years
Enrollment
319 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
37
States / cities
Tuscaloosa, Alabama • Tucson, Arizona • Little Rock, Arkansas + 34 more
Source: ClinicalTrials.gov public record
Updated Apr 11, 2014 · Synced Nov 2, 2026, 6:41 PM EST
Completed Phase 3 Interventional Results available

Explore the Efficacy and Safety of Once-daily Oral Rivaroxaban for the Prevention of Cardiovascular Events in Subjects With Nonvalvular Atrial Fibrillation Scheduled for Cardioversion

NCT01674647
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
Rivaroxaban (Xarelto, BAY59-7939), Vitamin K antagonist (VKA)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
1,504 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
66
States / cities
Mobile, Alabama • Scottsdale, Arizona • East Palo Alto, California + 58 more
Source: ClinicalTrials.gov public record
Updated Apr 30, 2015 · Synced Nov 2, 2026, 6:41 PM EST
Completed Phase 1 Interventional Accepts healthy volunteers

Open-label Trial to Evaluate the Effect Carbamazepine on Darigabat Pharmacokinetics in Healthy Adult Participants

NCT05824143
View directory record Official record
Conditions
Healthy Participants
Interventions
Darigabat, Carbamazepine
Drug
Lead sponsor
Cerevel Therapeutics, LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Aug 3, 2023 · Synced Nov 2, 2026, 6:41 PM EST
Completed No phase listed Observational

A Long-term Safety Study of Infliximab (Remicade)

NCT00261976
View directory record Official record
Conditions
Arthritis, Rheumatoid, Crohn Disease, Psoriasis
Interventions
Infliximab (Remicade)
Drug
Lead sponsor
Centocor, Inc.
Industry
Eligibility
Not listed
Enrollment
2,971 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2012
U.S. locations
100
States / cities
Birmingham, Alabama • Huntsville, Alabama • Montgomery, Alabama + 97 more
Source: ClinicalTrials.gov public record
Updated Mar 18, 2014 · Synced Nov 2, 2026, 6:41 PM EST